BMO Capital: 'Eli Lilly (LLY) to Acquire Precision I&I Biotech Merida Bio'
Tweet Send to a Friend
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $1,400.00 price target on Eli Lilly (NYSE: LLY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
